101
|
Characterization of cetuximab Fc/2 dimers by off-line CZE-MS. Anal Chim Acta 2016; 908:168-76. [PMID: 26826699 DOI: 10.1016/j.aca.2015.12.033] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2015] [Revised: 12/12/2015] [Accepted: 12/17/2015] [Indexed: 11/30/2022]
Abstract
Monoclonal antibody (mAb) therapeutics attract the largest concern due to their strong therapeutic potency and specificity. The Fc region of mAbs is common to many new biotherapeutics as biosimilar, antibody drug conjugate or fusion protein. Fc region has consequences for Fc-mediated effector functions that might be desirable for therapeutic applications. As a consequence, there is a continuous need for improvement of analytical methods to enable fast and accurate characterization of biotherapeutics. Capillary zone electrophoresis-Mass spectrometry couplings (CZE-MS) appear really attractive methods for the characterization of biological samples. In this report, we used CZE-MS systems developed in house and native MS infusion to allow precise middle-up characterization of Fc/2 variant of cetuximab. Molecular weights were measured for three Fc/2 charge variants detected in the CZE separation of cetuximab subunits. Two Fc/2 C-terminal lysine variants were identified and separated. As the aim is to understand the presence of three peaks in the CZE separation for two Fc/2 subunits, we developed a strategy using CZE-UV/MALDI-MS and CZE-UV/ESI-MS to evaluate the role of N-glycosylation and C-terminal lysine truncation on the CZE separation. The chemical structure of N-glycosylation expressed on the Fc region of cetuximab does not influence CZE separation while C-terminal lysine is significantly influencing separation. In addition, native MS infusion demonstrated the characterization of Fc/2 dimers at pH 5.7 and 6.8 and the first separation of these dimers using CZE-MS.
Collapse
|
102
|
Sjögren J, Olsson F, Beck A. Rapid and improved characterization of therapeutic antibodies and antibody related products using IdeS digestion and subunit analysis. Analyst 2016; 141:3114-25. [DOI: 10.1039/c6an00071a] [Citation(s) in RCA: 68] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Antibody subunits LC, Fd and Fc/2, generated by IdeS digestion has been applied in analytical methodologies to characterize antibody quality attributes such as glycosylation, oxidation, deamidation, and identity.
Collapse
Affiliation(s)
| | | | - Alain Beck
- Centre d'Immunologie Pierre Fabre
- St Julien-en-Genevois
- France
| |
Collapse
|
103
|
Ponniah G, Nowak C, Kita A, Cheng G, Kori Y, Liu H. Conformational changes of recombinant monoclonal antibodies by limited proteolytic digestion, stable isotope labeling, and liquid chromatography-mass spectrometry. Anal Biochem 2015; 497:1-7. [PMID: 26747642 DOI: 10.1016/j.ab.2015.12.008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2015] [Revised: 11/28/2015] [Accepted: 12/14/2015] [Indexed: 01/10/2023]
Abstract
Limited proteolytic digestion is a method with a long history that has been used to study protein domain structures and conformational changes. A method of combining limited proteolytic digestion, stable isotope labeling, and mass spectrometry was established in the current study to investigate protein conformational changes. Recombinant monoclonal antibodies with or without the conserved oligosaccharides, and with or without oxidation of the conserved methionine residues, were used to test the newly proposed method. All of the samples were digested in ammonium bicarbonate buffer prepared in normal water. The oxidized deglycosylated sample was also digested in ammonium bicarbonate buffer prepared in (18)O-labeled water. The sample from the digestion in (18)O-water was spiked into each sample digested in normal water. Each mixed sample was subsequently analyzed by liquid chromatography-mass spectrometry (LC-MS). The molecular weight differences between the peptides digested in normal water versus (18)O-water were used to differentiate peaks from the samples. The relative peak intensities of peptides with or without the C-terminal incorporation of (18)O atoms were used to determine susceptibility of different samples to trypsin and chymotrypsin. The results demonstrated that the method was capable of detecting local conformational changes of the recombinant monoclonal antibodies caused by deglycosylation and oxidation.
Collapse
Affiliation(s)
| | - Christine Nowak
- Product Characterization, Alexion Pharmaceuticals, Cheshire, CT 06410, USA
| | - Adriana Kita
- Product Characterization, Alexion Pharmaceuticals, Cheshire, CT 06410, USA
| | - Guilong Cheng
- Product Characterization, Alexion Pharmaceuticals, Cheshire, CT 06410, USA
| | - Yekaterina Kori
- Product Characterization, Alexion Pharmaceuticals, Cheshire, CT 06410, USA
| | - Hongcheng Liu
- Product Characterization, Alexion Pharmaceuticals, Cheshire, CT 06410, USA.
| |
Collapse
|
104
|
Fekete S, Guillarme D, Sandra P, Sandra K. Chromatographic, Electrophoretic, and Mass Spectrometric Methods for the Analytical Characterization of Protein Biopharmaceuticals. Anal Chem 2015; 88:480-507. [DOI: 10.1021/acs.analchem.5b04561] [Citation(s) in RCA: 171] [Impact Index Per Article: 19.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Affiliation(s)
- Szabolcs Fekete
- School
of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Boulevard d’Yvoy 20, 1211 Geneva 4, Switzerland
| | - Davy Guillarme
- School
of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Boulevard d’Yvoy 20, 1211 Geneva 4, Switzerland
| | - Pat Sandra
- Research Institute for Chromatography (RIC), President Kennedypark 26, 8500 Kortrijk, Belgium
| | - Koen Sandra
- Research Institute for Chromatography (RIC), President Kennedypark 26, 8500 Kortrijk, Belgium
| |
Collapse
|
105
|
Martínez-Ortega A, Herrera A, Salmerón-García A, Cabeza J, Cuadros-Rodríguez L, Navas N. Study and ICH validation of a reverse-phase liquid chromatographic method for the quantification of the intact monoclonal antibody cetuximab. J Pharm Anal 2015; 6:117-124. [PMID: 29403971 PMCID: PMC5762446 DOI: 10.1016/j.jpha.2015.11.007] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2015] [Revised: 11/23/2015] [Accepted: 11/25/2015] [Indexed: 01/31/2023] Open
Abstract
Cetuximab (CTX) is a potent chimeric mouse/human monoclonal antibody (mAb) approved worldwide for treatment of metastatic colorectal cancer. Among the various biological and physical analyses performed for full study on this biopharmaceutic, the determination of the concentration preparations throughout manufacturing and subsequent handling in hospital is particularly relevant. In the present work, the study and validation of a method for quantifying intact CTX by reverse-phase high-performance liquid chromatography with diode array detection ((RP)HPLC/DAD) is presented. With that end, we checked the performance of a chromatographic method for quantifying CTX and conducted a study to validate the method as stability-indicating in accordance with the International Conference on Harmonization guidelines (ICH) for biotechnological drugs; therefore, we evaluated linearity, accuracy, precision, detection and quantification limits, robustness and system suitability. The specificity of the method and the robustness of the mAb formulation against external stress factors were estimated by comprehensive chromatographic analysis by subjecting CTX to several informative stress conditions. As demonstrated, the method is rapid, accurate, and reproducible for CTX quantification. It was also successfully used to quantify CTX in a long-term stability study performed under hospital conditions.
Collapse
Affiliation(s)
- Antonio Martínez-Ortega
- Department of Analytical Chemistry, University of Granada, Faculty of Science, Campus Fuentenueva s/n, E-18071 Granada, Spain
| | - Agustín Herrera
- Department of Analytical Chemistry, University of Granada, Faculty of Science, Campus Fuentenueva s/n, E-18071 Granada, Spain
| | - Antonio Salmerón-García
- UGC Intercentro Interniveles Farmacia Granada, San Cecilio Hospital, Biomedical Research Institute ibs. GRANADA. Hospitales Universitarios de Granada, University of Granada, E-18012 Granada, Spain
| | - José Cabeza
- UGC Intercentro Interniveles Farmacia Granada, San Cecilio Hospital, Biomedical Research Institute ibs. GRANADA. Hospitales Universitarios de Granada, University of Granada, E-18012 Granada, Spain
| | - Luis Cuadros-Rodríguez
- Department of Analytical Chemistry, Science Faculty, Biomedical Research Institute ibis. GRANADA, University of Granada, Campus Fuentenueva s/n, E-18071 Granada, Spain
| | - Natalia Navas
- Department of Analytical Chemistry, Science Faculty, Biomedical Research Institute ibis. GRANADA, University of Granada, Campus Fuentenueva s/n, E-18071 Granada, Spain
| |
Collapse
|
106
|
Zhang L, Luo S, Zhang B. Glycan analysis of therapeutic glycoproteins. MAbs 2015; 8:205-15. [PMID: 26599345 PMCID: PMC4966609 DOI: 10.1080/19420862.2015.1117719] [Citation(s) in RCA: 126] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2015] [Revised: 10/26/2015] [Accepted: 11/02/2015] [Indexed: 01/02/2023] Open
Abstract
Therapeutic monoclonal antibodies (mAbs) are glycoproteins produced by living cell systems. The glycan moieties attached to the proteins can directly affect protein stability, bioactivity, and immunogenicity. Therefore, glycan variants of a glycoprotein product must be adequately analyzed and controlled to ensure product quality. However, the inherent complexity of protein glycosylation poses a daunting analytical challenge. This review provides an update of recent advances in glycan analysis, including the potential utility of lectin-based microarray for high throughput glycan profiling. Emphasis is placed on comparison of the major types of analytics for use in determining unique glycan features such as glycosylation site, glycan structure, and content.
Collapse
Affiliation(s)
- Lei Zhang
- Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland
| | - Shen Luo
- Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland
| | - Baolin Zhang
- Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland
| |
Collapse
|
107
|
Dotz V, Haselberg R, Shubhakar A, Kozak RP, Falck D, Rombouts Y, Reusch D, Somsen GW, Fernandes DL, Wuhrer M. Mass spectrometry for glycosylation analysis of biopharmaceuticals. Trends Analyt Chem 2015. [DOI: 10.1016/j.trac.2015.04.024] [Citation(s) in RCA: 62] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
108
|
|
109
|
Orthogonal Technologies for NISTmAb N-Glycan Structure Elucidation and Quantitation. ACTA ACUST UNITED AC 2015. [DOI: 10.1021/bk-2015-1201.ch004] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/20/2023]
|
110
|
Borotto NB, Zhou Y, Hollingsworth SR, Hale JE, Graban EM, Vaughan RC, Vachet RW. Investigating Therapeutic Protein Structure with Diethylpyrocarbonate Labeling and Mass Spectrometry. Anal Chem 2015; 87:10627-34. [PMID: 26399599 DOI: 10.1021/acs.analchem.5b03180] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Protein therapeutics are rapidly transforming the pharmaceutical industry. Unlike for small molecule therapeutics, current technologies are challenged to provide the rapid, high-resolution analyses of protein higher order structures needed to ensure drug efficacy and safety. Consequently, significant attention has turned to developing new methods that can quickly, accurately, and reproducibly characterize the three-dimensional structure of protein therapeutics. In this work, we describe a method that uses diethylpyrocarbonate (DEPC) labeling and mass spectrometry to detect three-dimensional structural changes in therapeutic proteins that have been exposed to degrading conditions. Using β2-microglobulin, immunoglobulin G1, and human growth hormone as model systems, we demonstrate that DEPC labeling can identify both specific protein regions that mediate aggregation and those regions that undergo more subtle structural changes upon mishandling of these proteins. Importantly, DEPC labeling is able to provide information for up to 30% of the surface residues in a given protein, thereby providing excellent structural resolution. Given the simplicity of the DEPC labeling chemistry and the relatively straightforward mass spectral analysis of DEPC-labeled proteins, we expect this method should be amenable to a wide range of protein therapeutics and their different formulations.
Collapse
Affiliation(s)
- Nicholas B Borotto
- Department of Chemistry, University of Massachusetts , Amherst, Massachusetts 01003, United States
| | - Yuping Zhou
- Department of Chemistry, University of Massachusetts , Amherst, Massachusetts 01003, United States
| | - Stephen R Hollingsworth
- Department of Molecular and Cellular Biochemistry, Indiana University , Bloomington, Indiana 47405, United States
| | - John E Hale
- QuarryBio , Bloomington, Indiana 47404, United States
| | - Eric M Graban
- QuarryBio , Bloomington, Indiana 47404, United States
| | - Robert C Vaughan
- Department of Molecular and Cellular Biochemistry, Indiana University , Bloomington, Indiana 47405, United States
| | - Richard W Vachet
- Department of Chemistry, University of Massachusetts , Amherst, Massachusetts 01003, United States
| |
Collapse
|
111
|
Abstract
Hypersensitivity in the allergic setting refers to immune reactions, stimulated by soluble antigens that can be rapidly progressing and, in the case of anaphylaxis, are occasionally fatal. As the number of known exposures associated with anaphylaxis is limited, identification of novel causative agents is important in facilitating both education and other allergen-specific approaches that are crucial to long-term risk management. Within the last 10 years, several seemingly separate observations were recognized to be related, all of which resulted from the development of antibodies to a carbohydrate moiety on proteins where exposure differed from airborne allergens but which were nevertheless capable of producing anaphylactic and hypersensitivity reactions. Our recent work has identified these responses as being due to a novel IgE antibody directed against a mammalian oligosaccharide epitope, galactose-alpha-1,3-galactose (alpha-gal). This review will present the history and biology of alpha-gal and discuss our current approach to management of the mammalian meat allergy and delayed anaphylaxis.
Collapse
|
112
|
A rapid approach for characterization of thiol-conjugated antibody–drug conjugates and calculation of drug–antibody ratio by liquid chromatography mass spectrometry. Anal Biochem 2015; 485:34-42. [DOI: 10.1016/j.ab.2015.06.001] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2015] [Revised: 05/28/2015] [Accepted: 06/01/2015] [Indexed: 12/11/2022]
|
113
|
Gahoual R, Biacchi M, Chicher J, Kuhn L, Hammann P, Beck A, Leize-Wagner E, François YN. Monoclonal antibodies biosimilarity assessment using transient isotachophoresis capillary zone electrophoresis-tandem mass spectrometry. MAbs 2015; 6:1464-73. [PMID: 25484058 DOI: 10.4161/mabs.36305] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Out of all categories, monoclonal antibody (mAb) therapeutics attract the most interest due to their strong therapeutic potency and specificity. Six of the 10 top-selling drugs are antibody-based therapeutics that will lose patent protection soon. The European Medicines Agency has pioneered the regulatory framework for approval of biosimilar products and approved the first biosimilar antibodies by the end of 2013. As highly complex glycoproteins with a wide range of micro-variants, mAbs require extensive characterization through multiple analytical methods for structure assessment rendering manufacturing control and biosimilarity studies particularly product and time-consuming. Here, capillary zone electrophoresis coupled to mass spectrometry by a sheathless interface (CESI-MS) was used to characterize marketed reference mAbs and their respective biosimilar candidate simultaneously over different facets of their primary structure. CESI-MS/MS data were compared between approved mAbs and their biosimilar candidates to prove/disconfirm biosimilarity regarding recent regulation directives. Using only a single sample injection of 200 fmol, CESI-MS/MS data enabled 100% amino acids (AA) sequence characterization, which allows a difference of even one AA between 2 samples to be distinguished precisely. Simultaneously glycoforms were characterized regarding their structures and position through fragmentation spectra and glycoforms semiquantitative analysis was established, showing the capacity of the developed methodology to detect up to 16 different glycans. Other posttranslational modifications hotspots were characterized while their relative occurrence levels were estimated and compared to biosimilars. These results proved the value of using CESI-MS because the separation selectivity and ionization efficiency provided by the system allowed substantial improvement in the characterization workflow robustness and accuracy. Biosimilarity assessment could be performed routinely with a single injection of each candidate enabling improvements in the biosimilar development pipeline.
Collapse
Affiliation(s)
- Rabah Gahoual
- a Laboratoire de spectrométrie de masse des interactions et des systèmes (LSMIS); CNRS - UMR 7140 , Université de Strasbourg , Strasbourg Cedex , France
| | | | | | | | | | | | | | | |
Collapse
|
114
|
Abstract
INTRODUCTION Glycans are increasingly important in the development of new biopharmaceuticals with optimized efficacy, half-life, and antigenicity. Current expression platforms for recombinant glycoprotein therapeutics typically do not produce homogeneous glycans and frequently display non-human glycans which may cause unwanted side effects. To circumvent these issues, glyco-engineering has been applied to different expression systems including mammalian cells, insect cells, yeast, and plants. AREAS COVERED This review summarizes recent developments in glyco-engineering focusing mainly on in vivo expression systems for recombinant proteins. The highlighted strategies aim at producing glycoproteins with homogeneous N- and O-linked glycans of defined composition. EXPERT OPINION Glyco-engineering of expression platforms is increasingly recognized as an important strategy to improve biopharmaceuticals. A better understanding and control of the factors leading to glycan heterogeneity will allow simplified production of recombinant glycoprotein therapeutics with less variation in terms of glycosylation. Further technological advances will have a major impact on manufacturing processes and may provide a completely new class of glycoprotein therapeutics with customized functions.
Collapse
Affiliation(s)
- Martina Dicker
- a 1 University of Natural Resources and Life Sciences , Department of Applied Genetics and Cell Biology , Muthgasse 18, Vienna, Austria
| | - Richard Strasser
- b 2 University of Natural Resources and Life Sciences, Department of Applied Genetics and Cell Biology , Muthgasse 18, Vienna, Austria +43 1 47654 6705 ; +43 1 47654 6392 ;
| |
Collapse
|
115
|
Sjögren J, Cosgrave EFJ, Allhorn M, Nordgren M, Björk S, Olsson F, Fredriksson S, Collin M. EndoS and EndoS2 hydrolyze Fc-glycans on therapeutic antibodies with different glycoform selectivity and can be used for rapid quantification of high-mannose glycans. Glycobiology 2015; 25:1053-63. [PMID: 26156869 PMCID: PMC4551147 DOI: 10.1093/glycob/cwv047] [Citation(s) in RCA: 62] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2015] [Accepted: 07/03/2015] [Indexed: 12/16/2022] Open
Abstract
Enzymes that affect glycoproteins of the human immune system, and thereby modulate defense responses, are abundant among bacterial pathogens. Two endoglycosidases from the human pathogen Streptococcus pyogenes, EndoS and EndoS2, have recently been shown to hydrolyze N-linked glycans of human immunoglobulin G. However, detailed characterization and comparison of the hydrolyzing activities have not been performed. In the present study, we set out to characterize the enzymes by comparing the activities of EndoS and EndoS2 on a selection of therapeutic monoclonal antibodies (mAbs), cetuximab, adalimumab, panitumumab and denosumab. By analyzing the glycans hydrolyzed by EndoS and EndoS2 from the antibodies using matrix-assisted laser desorption ionization time of flight, we found that both the enzymes cleaved complex glycans and that EndoS2 hydrolyzed hybrid and oligomannose structures to a greater extent compared with EndoS. A comparison of ultra-high-performance liquid chromatography (LC) profiles of the glycan pool of cetuximab hydrolyzed with EndoS and EndoS2 showed that EndoS2 hydrolyzed hybrid and oligomannose glycans, whereas these peaks were missing in the EndoS chromatogram. We utilized this difference in glycoform selectivity, in combination with the IdeS protease, and developed a LC separation method to quantify high mannose content in the Fc fragments of the selected mAbs. We conclude that EndoS and EndoS2 hydrolyze different glycoforms from the Fc-glycosylation site on therapeutic mAbs and that this can be used for rapid quantification of high mannose content.
Collapse
Affiliation(s)
- Jonathan Sjögren
- Division of Infection Medicine, Department of Clinical Sciences, Lund University, Lund 221 84, Sweden Genovis AB, Lund 200 07, Sweden
| | | | - Maria Allhorn
- Division of Infection Medicine, Department of Clinical Sciences, Lund University, Lund 221 84, Sweden
| | | | | | | | | | - Mattias Collin
- Division of Infection Medicine, Department of Clinical Sciences, Lund University, Lund 221 84, Sweden
| |
Collapse
|
116
|
Sedlák E, Schaefer JV, Marek J, Gimeson P, Plückthun A. Advanced analyses of kinetic stabilities of iggs modified by mutations and glycosylation. Protein Sci 2015; 24:1100-13. [PMID: 25966898 DOI: 10.1002/pro.2691] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2015] [Revised: 04/11/2015] [Accepted: 04/29/2015] [Indexed: 01/07/2023]
Abstract
The stability of Immunoglobulin G (IgG) affects production, storage and usability, especially in the clinic. The complex thermal and isothermal transitions of IgGs, especially their irreversibilities, pose a challenge to the proper determination of parameters describing their thermodynamic and kinetic stability. Here, we present a reliable mathematical model to study the irreversible thermal denaturations of antibody variants. The model was applied to two unrelated IgGs and their variants with stabilizing mutations as well as corresponding non-glycosylated forms of IgGs and Fab fragments. Thermal denaturations of IgGs were analyzed with three transitions, one reversible transition corresponding to C(H)2 domain unfolding followed by two consecutive irreversible transitions corresponding to Fab and C(H)3 domains, respectively. The parameters obtained allowed us to examine the effects of these mutations on the stabilities of individual domains within the full-length IgG. We found that the kinetic stability of the individual Fab fragment is significantly lowered within the IgG context, possibly because of intramolecular aggregation upon heating, while the stabilizing mutations have an especially beneficial effect. Thermal denaturations of non-glycosylated variants of IgG consist of more than three transitions and could not be analyzed by our model. However, isothermal denaturations demonstrated that the lack of glycosylation affects the stability of all and not just of the C(H)2 domain, suggesting that the partially unfolded domains may interact with each other during unfolding. Investigating thermal denaturation of IgGs according to our model provides a valuable tool for detecting subtle changes in thermodynamic and/or kinetic stabilities of individual domains.
Collapse
Affiliation(s)
- Erik Sedlák
- Department of Biochemistry, University of Zurich, Winterthurerstrasse 190, CH-8057, Zurich, Switzerland.,Centre for Interdisciplinary Biosciences, P.J. Šafárik University, Moyzesova 11, Košice, 040 01, Slovakia.,Department of Biochemistry, P.J. Šafárik University, Moyzesova 11, Košice, 040 01, Slovakia
| | - Jonas V Schaefer
- Department of Biochemistry, University of Zurich, Winterthurerstrasse 190, CH-8057, Zurich, Switzerland
| | - Jozef Marek
- Department of Biophysics, Institute of Experimental Physics, Watsonova 47, Košice, 040 01, Slovakia
| | - Peter Gimeson
- Malvern Instruments Inc., Northampton, Massachusetts, 01060-2327
| | - Andreas Plückthun
- Department of Biochemistry, University of Zurich, Winterthurerstrasse 190, CH-8057, Zurich, Switzerland
| |
Collapse
|
117
|
Asperger A, Marx K, Albers C, Molin L, Pinato O. Low Abundant N-linked Glycosylation in Hen Egg White Lysozyme Is Localized at Nonconsensus Sites. J Proteome Res 2015; 14:2633-41. [DOI: 10.1021/acs.jproteome.5b00175] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Arndt Asperger
- Bruker Daltonik GmbH, Fahrenheitstrasse
4, 28359 Bremen, Germany
| | - Kristina Marx
- Bruker Daltonik GmbH, Fahrenheitstrasse
4, 28359 Bremen, Germany
| | - Christian Albers
- Bruker Daltonik GmbH, Fahrenheitstrasse
4, 28359 Bremen, Germany
| | - Laura Molin
- Chelab Silliker, Via Fratta
25, 31023 Resana, Italy
| | - Odra Pinato
- Chelab Silliker, Via Fratta
25, 31023 Resana, Italy
| |
Collapse
|
118
|
Biacchi M, Gahoual R, Said N, Beck A, Leize-Wagner E, François YN. Glycoform Separation and Characterization of Cetuximab Variants by Middle-up Off-Line Capillary Zone Electrophoresis-UV/Electrospray Ionization-MS. Anal Chem 2015; 87:6240-50. [DOI: 10.1021/acs.analchem.5b00928] [Citation(s) in RCA: 66] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
- Michael Biacchi
- Laboratoire de Spectrométrie de
Masse des Interactions et des Systèmes (LSMIS), UDS-CNRS UMR
7140, Université de Strasbourg, Strasbourg 67000, France
| | - Rabah Gahoual
- Laboratoire de Spectrométrie de
Masse des Interactions et des Systèmes (LSMIS), UDS-CNRS UMR
7140, Université de Strasbourg, Strasbourg 67000, France
| | - Nassur Said
- Laboratoire de Spectrométrie de
Masse des Interactions et des Systèmes (LSMIS), UDS-CNRS UMR
7140, Université de Strasbourg, Strasbourg 67000, France
| | - Alain Beck
- Centre d’Immunologie Pierre Fabre, Saint-Julien-en-Genevois 74164, France
| | - Emmanuelle Leize-Wagner
- Laboratoire de Spectrométrie de
Masse des Interactions et des Systèmes (LSMIS), UDS-CNRS UMR
7140, Université de Strasbourg, Strasbourg 67000, France
| | - Yannis-Nicolas François
- Laboratoire de Spectrométrie de
Masse des Interactions et des Systèmes (LSMIS), UDS-CNRS UMR
7140, Université de Strasbourg, Strasbourg 67000, France
| |
Collapse
|
119
|
Beck S, Michalski A, Raether O, Lubeck M, Kaspar S, Goedecke N, Baessmann C, Hornburg D, Meier F, Paron I, Kulak NA, Cox J, Mann M. The Impact II, a Very High-Resolution Quadrupole Time-of-Flight Instrument (QTOF) for Deep Shotgun Proteomics. Mol Cell Proteomics 2015; 14:2014-29. [PMID: 25991688 PMCID: PMC4587313 DOI: 10.1074/mcp.m114.047407] [Citation(s) in RCA: 126] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2014] [Indexed: 11/06/2022] Open
Abstract
Hybrid quadrupole time-of-flight (QTOF) mass spectrometry is one of the two major principles used in proteomics. Although based on simple fundamentals, it has over the last decades greatly evolved in terms of achievable resolution, mass accuracy, and dynamic range. The Bruker impact platform of QTOF instruments takes advantage of these developments and here we develop and evaluate the impact II for shotgun proteomics applications. Adaption of our heated liquid chromatography system achieved very narrow peptide elution peaks. The impact II is equipped with a new collision cell with both axial and radial ion ejection, more than doubling ion extraction at high tandem MS frequencies. The new reflectron and detector improve resolving power compared with the previous model up to 80%, i.e. to 40,000 at m/z 1222. We analyzed the ion current from the inlet capillary and found very high transmission (>80%) up to the collision cell. Simulation and measurement indicated 60% transfer into the flight tube. We adapted MaxQuant for QTOF data, improving absolute average mass deviations to better than 1.45 ppm. More than 4800 proteins can be identified in a single run of HeLa digest in a 90 min gradient. The workflow achieved high technical reproducibility (R2 > 0.99) and accurate fold change determination in spike-in experiments in complex mixtures. Using label-free quantification we rapidly quantified haploid against diploid yeast and characterized overall proteome differences in mouse cell lines originating from different tissues. Finally, after high pH reversed-phase fractionation we identified 9515 proteins in a triplicate measurement of HeLa peptide mixture and 11,257 proteins in single measurements of cerebellum—the highest proteome coverage reported with a QTOF instrument so far.
Collapse
Affiliation(s)
- Scarlet Beck
- From the ‡Proteomics and Signal Transduction, Max-Planck-Institute of Biochemistry, Am Klopferspitz 18, 82152 Martinsried, Germany
| | | | - Oliver Raether
- §Bruker Daltonik GmbH, Fahrenheitstr. 4, 28359 Bremen, Germany
| | - Markus Lubeck
- §Bruker Daltonik GmbH, Fahrenheitstr. 4, 28359 Bremen, Germany
| | | | - Niels Goedecke
- §Bruker Daltonik GmbH, Fahrenheitstr. 4, 28359 Bremen, Germany
| | | | - Daniel Hornburg
- From the ‡Proteomics and Signal Transduction, Max-Planck-Institute of Biochemistry, Am Klopferspitz 18, 82152 Martinsried, Germany
| | - Florian Meier
- From the ‡Proteomics and Signal Transduction, Max-Planck-Institute of Biochemistry, Am Klopferspitz 18, 82152 Martinsried, Germany
| | - Igor Paron
- From the ‡Proteomics and Signal Transduction, Max-Planck-Institute of Biochemistry, Am Klopferspitz 18, 82152 Martinsried, Germany
| | - Nils A Kulak
- From the ‡Proteomics and Signal Transduction, Max-Planck-Institute of Biochemistry, Am Klopferspitz 18, 82152 Martinsried, Germany
| | - Juergen Cox
- ¶Computational Systems Biochemistry, Max-Planck-Institute of Biochemistry, Am Klopferspitz 18, 82152 Martinsried, Germany
| | - Matthias Mann
- From the ‡Proteomics and Signal Transduction, Max-Planck-Institute of Biochemistry, Am Klopferspitz 18, 82152 Martinsried, Germany;
| |
Collapse
|
120
|
Steinke JW, Platts-Mills TAE, Commins SP. The alpha-gal story: lessons learned from connecting the dots. J Allergy Clin Immunol 2015; 135:589-96; quiz 597. [PMID: 25747720 DOI: 10.1016/j.jaci.2014.12.1947] [Citation(s) in RCA: 226] [Impact Index Per Article: 25.1] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2014] [Revised: 11/21/2014] [Accepted: 12/10/2014] [Indexed: 10/23/2022]
Abstract
Anaphylaxis is a severe allergic reaction that can be rapidly progressing and fatal, and therefore establishing its cause is pivotal to long-term risk management. Our recent work has identified a novel IgE antibody response to a mammalian oligosaccharide epitope, galactose-alpha-1,3-galactose (alpha-gal). IgE to alpha-gal has been associated with 2 distinct forms of anaphylaxis: (1) immediate-onset anaphylaxis during first exposure to intravenous cetuximab and (2) delayed-onset anaphylaxis 3 to 6 hours after ingestion of mammalian food products (eg, beef and pork). Results of our studies and those of others strongly suggest that tick bites are a cause, if not the only significant cause, of IgE antibody responses to alpha-gal in the southern, eastern, and central United States; Europe; Australia; and parts of Asia. Typical immune responses to carbohydrates are considered to be T-cell independent, whereas IgE antibody production is thought to involve sequential class-switching that requires input from T cells. Therefore, establishing the mechanism of the specific IgE antibody response to alpha-gal will be an important aspect to address as this area of research continues.
Collapse
Affiliation(s)
- John W Steinke
- Asthma and Allergic Diseases Center, Carter Immunology Center, Department of Medicine, University of Virginia Health System, Charlottesville, Va
| | - Thomas A E Platts-Mills
- Asthma and Allergic Diseases Center, Carter Immunology Center, Department of Medicine, University of Virginia Health System, Charlottesville, Va.
| | - Scott P Commins
- Asthma and Allergic Diseases Center, Carter Immunology Center, Department of Medicine, University of Virginia Health System, Charlottesville, Va
| |
Collapse
|
121
|
Ayoub D, Bertaccini D, Diemer H, Wagner-Rousset E, Colas O, Cianférani S, Van Dorsselaer A, Beck A, Schaeffer-Reiss C. Characterization of the N-Terminal Heterogeneities of Monoclonal Antibodies Using In-Gel Charge Derivatization of α-Amines and LC-MS/MS. Anal Chem 2015; 87:3784-90. [DOI: 10.1021/ac504427k] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Affiliation(s)
- Daniel Ayoub
- Centre d’Immunologie Pierre Fabre (CIPF), 5 Av. Napoléon III, BP 60497, 74164 Saint-Julien-en-Genevois, France
| | - Diego Bertaccini
- BioOrganic
Mass
Spectrometry Laboratory (LSMBO), IPHC, Université de Strasbourg, 25 rue Becquerel, 67087 Strasbourg, France
- IPHC, CNRS,
UMR7178, 67087 Strasbourg, France
| | - Hélène Diemer
- BioOrganic
Mass
Spectrometry Laboratory (LSMBO), IPHC, Université de Strasbourg, 25 rue Becquerel, 67087 Strasbourg, France
- IPHC, CNRS,
UMR7178, 67087 Strasbourg, France
| | - Elsa Wagner-Rousset
- Centre d’Immunologie Pierre Fabre (CIPF), 5 Av. Napoléon III, BP 60497, 74164 Saint-Julien-en-Genevois, France
| | - Olivier Colas
- Centre d’Immunologie Pierre Fabre (CIPF), 5 Av. Napoléon III, BP 60497, 74164 Saint-Julien-en-Genevois, France
| | - Sarah Cianférani
- BioOrganic
Mass
Spectrometry Laboratory (LSMBO), IPHC, Université de Strasbourg, 25 rue Becquerel, 67087 Strasbourg, France
- IPHC, CNRS,
UMR7178, 67087 Strasbourg, France
| | - Alain Van Dorsselaer
- BioOrganic
Mass
Spectrometry Laboratory (LSMBO), IPHC, Université de Strasbourg, 25 rue Becquerel, 67087 Strasbourg, France
- IPHC, CNRS,
UMR7178, 67087 Strasbourg, France
| | - Alain Beck
- Centre d’Immunologie Pierre Fabre (CIPF), 5 Av. Napoléon III, BP 60497, 74164 Saint-Julien-en-Genevois, France
| | - Christine Schaeffer-Reiss
- BioOrganic
Mass
Spectrometry Laboratory (LSMBO), IPHC, Université de Strasbourg, 25 rue Becquerel, 67087 Strasbourg, France
- IPHC, CNRS,
UMR7178, 67087 Strasbourg, France
| |
Collapse
|
122
|
Abstract
In 2007, the monoclonal antibody cetuximab caused severe hypersensitivity reactions during the first infusion in a region of the southeastern United States. Investigation of pretreatment sera established that they contained immunoglobulin (Ig) E against the oligosaccharide galactose-alpha-1,3-galactose (alpha-gal), which is present on the Fab of cetuximab. Alpha-gal is a blood group substance of nonprimate mammals. These IgE antibodies are also associated with delayed anaphylaxis to red meat (ie, to meat or organs of animals that carry this oligosaccharide). Evidence shows that the primary cause of these IgE antibodies is bites from the tick Amblyomma americanum or its larvae.
Collapse
|
123
|
Nicolardi S, Switzar L, Deelder AM, Palmblad M, van der Burgt YE. Top-Down MALDI-In-Source Decay-FTICR Mass Spectrometry of Isotopically Resolved Proteins. Anal Chem 2015; 87:3429-37. [DOI: 10.1021/ac504708y] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- Simone Nicolardi
- Center for Proteomics and
Metabolomics, Leiden University Medical Center (LUMC), PO Box 9600, 2300 RC, Leiden, The Netherlands
| | - Linda Switzar
- Center for Proteomics and
Metabolomics, Leiden University Medical Center (LUMC), PO Box 9600, 2300 RC, Leiden, The Netherlands
| | - André M. Deelder
- Center for Proteomics and
Metabolomics, Leiden University Medical Center (LUMC), PO Box 9600, 2300 RC, Leiden, The Netherlands
| | - Magnus Palmblad
- Center for Proteomics and
Metabolomics, Leiden University Medical Center (LUMC), PO Box 9600, 2300 RC, Leiden, The Netherlands
| | - Yuri E.M. van der Burgt
- Center for Proteomics and
Metabolomics, Leiden University Medical Center (LUMC), PO Box 9600, 2300 RC, Leiden, The Netherlands
| |
Collapse
|
124
|
Fekete S, Beck A, Veuthey JL, Guillarme D. Ion-exchange chromatography for the characterization of biopharmaceuticals. J Pharm Biomed Anal 2015; 113:43-55. [PMID: 25800161 DOI: 10.1016/j.jpba.2015.02.037] [Citation(s) in RCA: 164] [Impact Index Per Article: 18.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2014] [Revised: 02/18/2015] [Accepted: 02/19/2015] [Indexed: 12/28/2022]
Abstract
Ion-exchange chromatography (IEX) is a historical technique widely used for the detailed characterization of therapeutic proteins and can be considered as a reference and powerful technique for the qualitative and quantitative evaluation of charge heterogeneity. The goal of this review is to provide an overview of theoretical and practical aspects of modern IEX applied for the characterization of therapeutic proteins including monoclonal antibodies (Mabs) and antibody drug conjugates (ADCs). The section on method development describes how to select a suitable stationary phase chemistry and dimensions, the mobile phase conditions (pH, nature and concentration of salt), as well as the temperature and flow rate, considering proteins isoelectric point (pI). In addition, both salt-gradient and pH-gradient approaches were critically reviewed and benefits as well as limitations of these two strategies were provided. Finally, several applications, mostly from pharmaceutical industries, illustrate the potential of IEX for the characterization of charge variants of various types of biopharmaceutical products.
Collapse
Affiliation(s)
- Szabolcs Fekete
- School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Boulevard d'Yvoy 20, 1211 Geneva 4, Switzerland.
| | - Alain Beck
- Center of Immunology Pierre Fabre, 5 Avenue Napoléon III, BP 60497, 74160 Saint-Julien-en-Genevois, France(1)
| | - Jean-Luc Veuthey
- School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Boulevard d'Yvoy 20, 1211 Geneva 4, Switzerland
| | - Davy Guillarme
- School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Boulevard d'Yvoy 20, 1211 Geneva 4, Switzerland
| |
Collapse
|
125
|
An Y, Zhang Y, Mueller HM, Shameem M, Chen X. A new tool for monoclonal antibody analysis: application of IdeS proteolysis in IgG domain-specific characterization. MAbs 2015; 6:879-93. [PMID: 24927271 DOI: 10.4161/mabs.28762] [Citation(s) in RCA: 101] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
Monoclonal antibody (mAb) products are extraordinarily heterogeneous due to the presence of a variety of enzymatic and chemical modifications, such as deamidation, isomerization, oxidation, glycosylation, glycation, and terminal cyclization. The modifications in different domains of the antibody molecule can result in different biological consequences. Therefore, characterization and routine monitoring of domain-specific modifications are essential to ensure the quality of the therapeutic antibody products. For this purpose, a rapid and informative methodology was developed to examine the heterogeneity of individual domains in mAb products. A recently discovered endopeptidase, IdeS, cleaves heavy chains below the hinge region, producing F(ab') 2 and Fc fragments. Following reduction of disulfide bonds, three antibody domains (LC, Fd, and Fc/2) can be released for further characterization. Subsequent analyses by liquid chromatography/mass spectrometry, capillary isoelectric focusing, and glycan mapping enable domain-specific profiling of oxidation, charge heterogeneity, and glycoform distribution. When coupled with reversed phase chromatography, the unique chromatographic profile of each molecule offers a simple strategy for an identity test, which is an important formal test for biopharmaceutical quality control purposes. This methodology is demonstrated for a number of IgGs of different subclasses (IgG1, IgG2, IgG4), as well as an Fc fusion protein. The presented technique provides a convenient platform approach for scientific and formal therapeutic mAb product characterization. It can also be applied in regulated drug substance batch release and stability testing of antibody and Fc fusion protein products, in particular for identity and routine monitoring of domain-specific modifications.
Collapse
Affiliation(s)
- Yan An
- Sterile Product and Analytical Development; Merck Research Laboratories; Kenilworth, NJ USA
| | - Ying Zhang
- Sterile Product and Analytical Development; Merck Research Laboratories; Kenilworth, NJ USA
| | - Hans-Martin Mueller
- Sterile Product and Analytical Development; Merck Research Laboratories; Kenilworth, NJ USA
| | - Mohammed Shameem
- Sterile Product and Analytical Development; Merck Research Laboratories; Kenilworth, NJ USA
| | - Xiaoyu Chen
- Sterile Product and Analytical Development; Merck Research Laboratories; Kenilworth, NJ USA
| |
Collapse
|
126
|
Beck A, Debaene F, Diemer H, Wagner-Rousset E, Colas O, Van Dorsselaer A, Cianférani S. Cutting-edge mass spectrometry characterization of originator, biosimilar and biobetter antibodies. JOURNAL OF MASS SPECTROMETRY : JMS 2015; 50:285-297. [PMID: 25800010 DOI: 10.1002/jms.3554] [Citation(s) in RCA: 94] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/28/2014] [Revised: 11/18/2014] [Accepted: 11/24/2014] [Indexed: 06/04/2023]
Abstract
The approval process for antibody biosimilars relies primarily on comprehensive analytical data to establish comparability and high similarity with the originator. Mass spectrometry (MS) in combination with liquid chromatography (LC) and electrophoretic methods are the corner stone for comparability and biosimilarity evaluation. In this special feature we report head-to-head comparison of trastuzumab and cetuximab with corresponding biosimilar and biobetter candidates based on cutting-edge mass spectrometry techniques such as native MS and ion-mobility MS at different levels (top, middle and bottom). In addition, we discuss the advantages and the limitations of sample preparation and enzymatic digestion, middle-up and -down strategies and the use of hydrogen/deuterium exchange followed by MS (HDX-MS). Last but not least, emerging separation methods combined to MS such as capillary zone electrophoresis-tandem MS (CESI-MS/MS), electron transfer dissociation (ETD), top down-sequencing (TDS) and high-resolution MS (HR-MS) that complete the panel of state-of-the-art MS-based options for comparability and biosimilarity evaluation are presented.
Collapse
Affiliation(s)
- Alain Beck
- Centre d'Immunologie Pierre Fabre (CIPF), 5 Av. Napoléon III, BP 60497, 74164, Saint-Julien-en-Genevois, France
| | | | | | | | | | | | | |
Collapse
|
127
|
Abstract
Effective characterization of protein-based therapeutic candidates such as monoclonal antibodies (mAbs) is important to facilitate their successful progression from early discovery and development stages to marketing approval. One challenge relevant to biopharmaceutical development is, understanding how the stability of a protein is affected by the presence of an attached oligosaccharide, termed a glycan. To explore the utility of molecular dynamics simulations as a complementary technique to currently available experimental methods, the Fc fragment was employed as a model system to improve our understanding of protein stabilization by glycan attachment. Long molecular dynamics simulations were performed on three Fc glycoform variants modeled using the crystal structure of a human IgG1 mAb. Two of these three glycoform variants have their glycan carbohydrates partially or completely removed. Structural differences among the glycoform variants during simulations suggest that glycan truncation and/or removal can cause quaternary structural deformation of the Fc as a result of the loss or disruption of a significant number of inter-glycan contacts that are not formed in the human IgG1 crystal structure, but do form during simulations described here. Glycan truncation/removal can also increase the tertiary structural deformation of CH2 domains, demonstrating the importance of specific carbohydrates toward stabilizing individual CH2 domains. At elevated temperatures, glycan truncation can also differentially affect structural deformation in locations (Helix-1 and Helix-2) that are far from the oligosaccharide attachment point. Deformation of these helices, which form part of the FcRn, could affect binding if these regions are unable to refold after temperature normalization. During elevated temperature simulations of the deglycosylated variant, CH2 domains collapsed onto CH3 domains. Observations from these glycan truncation/removal simulations have improved our understanding on how glycan composition can affect mAb stability.
Collapse
Affiliation(s)
- Patrick M Buck
- Pharmaceutical Research and Development; Biotherapeutics Pharmaceutical Sciences; Pfizer Inc.; Chesterfield, MO USA
| | - Sandeep Kumar
- Pharmaceutical Research and Development; Biotherapeutics Pharmaceutical Sciences; Pfizer Inc.; Chesterfield, MO USA
| | - Satish K Singh
- Pharmaceutical Research and Development; Biotherapeutics Pharmaceutical Sciences; Pfizer Inc.; Chesterfield, MO USA
| |
Collapse
|
128
|
Fekete S, Beck A, Fekete J, Guillarme D. Method development for the separation of monoclonal antibody charge variants in cation exchange chromatography, Part I: Salt gradient approach. J Pharm Biomed Anal 2015; 102:33-44. [DOI: 10.1016/j.jpba.2014.08.035] [Citation(s) in RCA: 91] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2014] [Revised: 08/27/2014] [Accepted: 08/27/2014] [Indexed: 10/24/2022]
|
129
|
Formolo T, Ly M, Levy M, Kilpatrick L, Lute S, Phinney K, Marzilli L, Brorson K, Boyne M, Davis D, Schiel J. Determination of the NISTmAb Primary Structure. ACS SYMPOSIUM SERIES 2015. [DOI: 10.1021/bk-2015-1201.ch001] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/02/2022]
Affiliation(s)
- Trina Formolo
- Biomolecular Measurement Division, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, United States
- Mass Spectrometry and Biophysical Characterization, Analytical Research and Development, BioTherapeutics Pharmaceutical Sciences, Pfizer, Inc., Andover, Massachusetts 01810, United States
- Janssen Research and Development, LLC, Spring House, Pennsylvania 19002, United States
- Center for Drug Evaluation and Research, Office of Testing and Research, Division of Pharmaceutical Analysis, U.S. Food and Drug Administration, Saint Louis, Missouri 63110, United States
- Center for Drug Evaluation and Research, Office of Biotechnology Products, Division of Monoclonal Antibodies, U.S Food and Drug Administration, Silver Spring, Maryland 20993, United States
| | - Mellisa Ly
- Biomolecular Measurement Division, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, United States
- Mass Spectrometry and Biophysical Characterization, Analytical Research and Development, BioTherapeutics Pharmaceutical Sciences, Pfizer, Inc., Andover, Massachusetts 01810, United States
- Janssen Research and Development, LLC, Spring House, Pennsylvania 19002, United States
- Center for Drug Evaluation and Research, Office of Testing and Research, Division of Pharmaceutical Analysis, U.S. Food and Drug Administration, Saint Louis, Missouri 63110, United States
- Center for Drug Evaluation and Research, Office of Biotechnology Products, Division of Monoclonal Antibodies, U.S Food and Drug Administration, Silver Spring, Maryland 20993, United States
| | - Michaella Levy
- Biomolecular Measurement Division, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, United States
- Mass Spectrometry and Biophysical Characterization, Analytical Research and Development, BioTherapeutics Pharmaceutical Sciences, Pfizer, Inc., Andover, Massachusetts 01810, United States
- Janssen Research and Development, LLC, Spring House, Pennsylvania 19002, United States
- Center for Drug Evaluation and Research, Office of Testing and Research, Division of Pharmaceutical Analysis, U.S. Food and Drug Administration, Saint Louis, Missouri 63110, United States
- Center for Drug Evaluation and Research, Office of Biotechnology Products, Division of Monoclonal Antibodies, U.S Food and Drug Administration, Silver Spring, Maryland 20993, United States
| | - Lisa Kilpatrick
- Biomolecular Measurement Division, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, United States
- Mass Spectrometry and Biophysical Characterization, Analytical Research and Development, BioTherapeutics Pharmaceutical Sciences, Pfizer, Inc., Andover, Massachusetts 01810, United States
- Janssen Research and Development, LLC, Spring House, Pennsylvania 19002, United States
- Center for Drug Evaluation and Research, Office of Testing and Research, Division of Pharmaceutical Analysis, U.S. Food and Drug Administration, Saint Louis, Missouri 63110, United States
- Center for Drug Evaluation and Research, Office of Biotechnology Products, Division of Monoclonal Antibodies, U.S Food and Drug Administration, Silver Spring, Maryland 20993, United States
| | - Scott Lute
- Biomolecular Measurement Division, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, United States
- Mass Spectrometry and Biophysical Characterization, Analytical Research and Development, BioTherapeutics Pharmaceutical Sciences, Pfizer, Inc., Andover, Massachusetts 01810, United States
- Janssen Research and Development, LLC, Spring House, Pennsylvania 19002, United States
- Center for Drug Evaluation and Research, Office of Testing and Research, Division of Pharmaceutical Analysis, U.S. Food and Drug Administration, Saint Louis, Missouri 63110, United States
- Center for Drug Evaluation and Research, Office of Biotechnology Products, Division of Monoclonal Antibodies, U.S Food and Drug Administration, Silver Spring, Maryland 20993, United States
| | - Karen Phinney
- Biomolecular Measurement Division, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, United States
- Mass Spectrometry and Biophysical Characterization, Analytical Research and Development, BioTherapeutics Pharmaceutical Sciences, Pfizer, Inc., Andover, Massachusetts 01810, United States
- Janssen Research and Development, LLC, Spring House, Pennsylvania 19002, United States
- Center for Drug Evaluation and Research, Office of Testing and Research, Division of Pharmaceutical Analysis, U.S. Food and Drug Administration, Saint Louis, Missouri 63110, United States
- Center for Drug Evaluation and Research, Office of Biotechnology Products, Division of Monoclonal Antibodies, U.S Food and Drug Administration, Silver Spring, Maryland 20993, United States
| | - Lisa Marzilli
- Biomolecular Measurement Division, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, United States
- Mass Spectrometry and Biophysical Characterization, Analytical Research and Development, BioTherapeutics Pharmaceutical Sciences, Pfizer, Inc., Andover, Massachusetts 01810, United States
- Janssen Research and Development, LLC, Spring House, Pennsylvania 19002, United States
- Center for Drug Evaluation and Research, Office of Testing and Research, Division of Pharmaceutical Analysis, U.S. Food and Drug Administration, Saint Louis, Missouri 63110, United States
- Center for Drug Evaluation and Research, Office of Biotechnology Products, Division of Monoclonal Antibodies, U.S Food and Drug Administration, Silver Spring, Maryland 20993, United States
| | - Kurt Brorson
- Biomolecular Measurement Division, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, United States
- Mass Spectrometry and Biophysical Characterization, Analytical Research and Development, BioTherapeutics Pharmaceutical Sciences, Pfizer, Inc., Andover, Massachusetts 01810, United States
- Janssen Research and Development, LLC, Spring House, Pennsylvania 19002, United States
- Center for Drug Evaluation and Research, Office of Testing and Research, Division of Pharmaceutical Analysis, U.S. Food and Drug Administration, Saint Louis, Missouri 63110, United States
- Center for Drug Evaluation and Research, Office of Biotechnology Products, Division of Monoclonal Antibodies, U.S Food and Drug Administration, Silver Spring, Maryland 20993, United States
| | - Michael Boyne
- Biomolecular Measurement Division, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, United States
- Mass Spectrometry and Biophysical Characterization, Analytical Research and Development, BioTherapeutics Pharmaceutical Sciences, Pfizer, Inc., Andover, Massachusetts 01810, United States
- Janssen Research and Development, LLC, Spring House, Pennsylvania 19002, United States
- Center for Drug Evaluation and Research, Office of Testing and Research, Division of Pharmaceutical Analysis, U.S. Food and Drug Administration, Saint Louis, Missouri 63110, United States
- Center for Drug Evaluation and Research, Office of Biotechnology Products, Division of Monoclonal Antibodies, U.S Food and Drug Administration, Silver Spring, Maryland 20993, United States
| | - Darryl Davis
- Biomolecular Measurement Division, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, United States
- Mass Spectrometry and Biophysical Characterization, Analytical Research and Development, BioTherapeutics Pharmaceutical Sciences, Pfizer, Inc., Andover, Massachusetts 01810, United States
- Janssen Research and Development, LLC, Spring House, Pennsylvania 19002, United States
- Center for Drug Evaluation and Research, Office of Testing and Research, Division of Pharmaceutical Analysis, U.S. Food and Drug Administration, Saint Louis, Missouri 63110, United States
- Center for Drug Evaluation and Research, Office of Biotechnology Products, Division of Monoclonal Antibodies, U.S Food and Drug Administration, Silver Spring, Maryland 20993, United States
| | - John Schiel
- Biomolecular Measurement Division, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, United States
- Mass Spectrometry and Biophysical Characterization, Analytical Research and Development, BioTherapeutics Pharmaceutical Sciences, Pfizer, Inc., Andover, Massachusetts 01810, United States
- Janssen Research and Development, LLC, Spring House, Pennsylvania 19002, United States
- Center for Drug Evaluation and Research, Office of Testing and Research, Division of Pharmaceutical Analysis, U.S. Food and Drug Administration, Saint Louis, Missouri 63110, United States
- Center for Drug Evaluation and Research, Office of Biotechnology Products, Division of Monoclonal Antibodies, U.S Food and Drug Administration, Silver Spring, Maryland 20993, United States
| |
Collapse
|
130
|
Method development for the separation of monoclonal antibody charge variants in cation exchange chromatography, Part II: pH gradient approach. J Pharm Biomed Anal 2015; 102:282-9. [DOI: 10.1016/j.jpba.2014.09.032] [Citation(s) in RCA: 99] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2014] [Revised: 09/02/2014] [Accepted: 09/10/2014] [Indexed: 11/24/2022]
|
131
|
Wagner-Rousset E, Janin-Bussat MC, Colas O, Excoffier M, Ayoub D, Haeuw JF, Rilatt I, Perez M, Corvaïa N, Beck A. Antibody-drug conjugate model fast characterization by LC-MS following IdeS proteolytic digestion. MAbs 2014; 6:273-85. [PMID: 24135617 PMCID: PMC3929440 DOI: 10.4161/mabs.26773] [Citation(s) in RCA: 102] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Here we report the design and production of an antibody-fluorophore conjugate (AFC) as a non-toxic model of an antibody-drug conjugate (ADC). This AFC is based on the conjugation of dansyl sulfonamide ethyl amine (DSEA )-linker maleimide on interchain cysteines of trastuzumab used as a reference antibody. The resulting AFC was first characterized by routine analytical methods (SEC, SDS-PAGE, CE-SDS, HIC and native MS), resulting in similar chromatograms,electropherograms and mass spectra to those reported for hinge Cys-linked ADCs. IdeS digestion of the AFC was then performed, followed by reduction and analysis by liquid chromatography coupled to mass spectrometry analysis. Dye loading and distribution on light chain and Fd fragments were calculated, as well as the average dye to antibody ratio (DAR) for both monomeric and multimeric species. In addition, by analyzing the Fc fragment in the same run, full glycoprofiling and demonstration of the absence of additional conjugation was easily achieved. As for naked antibodies and Fc-fusion proteins, IdeS proteolytic digestion may rapidly become a reference analytical method at all stages of ADC discovery, preclinical and clinical development. The method can be routinely used for comparability assays, formulation, process scale-up and transfer, and to define critical quality attributes in a quality-by-design approach.
Collapse
|
132
|
Srzentić K, Fornelli L, Laskay ÜA, Monod M, Beck A, Ayoub D, Tsybin YO. Advantages of Extended Bottom-Up Proteomics Using Sap9 for Analysis of Monoclonal Antibodies. Anal Chem 2014; 86:9945-53. [DOI: 10.1021/ac502766n] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Affiliation(s)
- Kristina Srzentić
- Biomolecular
Mass Spectrometry Laboratory, Ecole Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland
| | - Luca Fornelli
- Biomolecular
Mass Spectrometry Laboratory, Ecole Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland
| | - Ünige A. Laskay
- Biomolecular
Mass Spectrometry Laboratory, Ecole Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland
| | - Michel Monod
- Department
of Dermatology, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland
| | - Alain Beck
- Centre d’Immunologie Pierre Fabre, 74160 St. Julien-en-Genevois, France
| | - Daniel Ayoub
- Biomolecular
Mass Spectrometry Laboratory, Ecole Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland
| | - Yury O. Tsybin
- Biomolecular
Mass Spectrometry Laboratory, Ecole Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland
| |
Collapse
|
133
|
Gahoual R, Busnel JM, Beck A, François YN, Leize-Wagner E. Full Antibody Primary Structure and Microvariant Characterization in a Single Injection Using Transient Isotachophoresis and Sheathless Capillary Electrophoresis–Tandem Mass Spectrometry. Anal Chem 2014; 86:9074-81. [DOI: 10.1021/ac502378e] [Citation(s) in RCA: 71] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Affiliation(s)
- Rabah Gahoual
- Laboratoire
de Spectrométrie de Masse des Interactions et des Systèmes
(LSMIS), UDS-CNRS UMR 7140, Université de Strasbourg, Strasbourg, France
| | | | - Alain Beck
- Centre d’immunologie
Pierre Fabre, Saint-Julien-en-Genevois, France
| | - Yannis-Nicolas François
- Laboratoire
de Spectrométrie de Masse des Interactions et des Systèmes
(LSMIS), UDS-CNRS UMR 7140, Université de Strasbourg, Strasbourg, France
| | - Emmanuelle Leize-Wagner
- Laboratoire
de Spectrométrie de Masse des Interactions et des Systèmes
(LSMIS), UDS-CNRS UMR 7140, Université de Strasbourg, Strasbourg, France
| |
Collapse
|
134
|
Bondt A, Rombouts Y, Selman MHJ, Hensbergen PJ, Reiding KR, Hazes JMW, Dolhain RJEM, Wuhrer M. Immunoglobulin G (IgG) Fab glycosylation analysis using a new mass spectrometric high-throughput profiling method reveals pregnancy-associated changes. Mol Cell Proteomics 2014; 13:3029-39. [PMID: 25004930 PMCID: PMC4223489 DOI: 10.1074/mcp.m114.039537] [Citation(s) in RCA: 193] [Impact Index Per Article: 19.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
The N-linked glycosylation of the constant fragment (Fc) of immunoglobulin G has been shown to change during pathological and physiological events and to strongly influence antibody inflammatory properties. In contrast, little is known about Fab-linked N-glycosylation, carried by ∼ 20% of IgG. Here we present a high-throughput workflow to analyze Fab and Fc glycosylation of polyclonal IgG purified from 5 μl of serum. We were able to detect and quantify 37 different N-glycans by means of MALDI-TOF-MS analysis in reflectron positive mode using a novel linkage-specific derivatization of sialic acid. This method was applied to 174 samples of a pregnancy cohort to reveal Fab glycosylation features and their change with pregnancy. Data analysis revealed marked differences between Fab and Fc glycosylation, especially in the levels of galactosylation and sialylation, incidence of bisecting GlcNAc, and presence of high mannose structures, which were all higher in the Fab portion than the Fc, whereas Fc showed higher levels of fucosylation. Additionally, we observed several changes during pregnancy and after delivery. Fab N-glycan sialylation was increased and bisection was decreased relative to postpartum time points, and nearly complete galactosylation of Fab glycans was observed throughout. Fc glycosylation changes were similar to results described before, with increased galactosylation and sialylation and decreased bisection during pregnancy. We expect that the parallel analysis of IgG Fab and Fc, as set up in this paper, will be important for unraveling roles of these glycans in (auto)immunity, which may be mediated via recognition by human lectins or modulation of antigen binding.
Collapse
Affiliation(s)
- Albert Bondt
- From the ‡Department of Rheumatology, Erasmus University Medical Center, 3000 CA Rotterdam, The Netherlands; §Center for Proteomics and Metabolomics, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
| | - Yoann Rombouts
- §Center for Proteomics and Metabolomics, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands; ¶Department of Rheumatology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
| | - Maurice H J Selman
- §Center for Proteomics and Metabolomics, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
| | - Paul J Hensbergen
- §Center for Proteomics and Metabolomics, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
| | - Karli R Reiding
- §Center for Proteomics and Metabolomics, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
| | - Johanna M W Hazes
- From the ‡Department of Rheumatology, Erasmus University Medical Center, 3000 CA Rotterdam, The Netherlands
| | - Radboud J E M Dolhain
- From the ‡Department of Rheumatology, Erasmus University Medical Center, 3000 CA Rotterdam, The Netherlands
| | - Manfred Wuhrer
- §Center for Proteomics and Metabolomics, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands; ‖Division of BioAnalytical Chemistry, VU University Amsterdam, 1081 HV Amsterdam, The Netherlands; **Department of Molecular Cell Biology and Immunology, VU University Medical Center, 1007 MB Amsterdam, The Netherlands
| |
Collapse
|
135
|
Nicolardi S, Deelder AM, Palmblad M, van der Burgt YEM. Structural analysis of an intact monoclonal antibody by online electrochemical reduction of disulfide bonds and Fourier transform ion cyclotron resonance mass spectrometry. Anal Chem 2014; 86:5376-82. [PMID: 24780057 DOI: 10.1021/ac500383c] [Citation(s) in RCA: 45] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Structural confirmation and quality control of recombinant monoclonal antibodies (mAbs) by top-down mass spectrometry is still challenging due to the size of the proteins, disulfide content, and post-translational modifications such as glycosylation. In this study we have applied electrochemistry (EC) to overcome disulfide bridge complexity in top-down analysis of mAbs. To this end, an electrochemical cell was coupled directly to an electrospray ionization (ESI) source and a Fourier transform ion cyclotron resonance (FTICR) mass spectrometer (MS) equipped with a 15 T magnet. By performing online EC-assisted reduction of interchain disulfide bonds in an intact mAb, the released light chains could be selected for tandem mass spectrometry (MS/MS) analysis without interference from heavy-chain fragments. Moreover, the acquisition of full MS scans under denaturing conditions allowed profiling of all abundant mAb glycoforms. Ultrahigh-resolution FTICR-MS measurements provided fully resolved isotopic distributions of intact mAb and enabled the identification of the most abundant adducts and other interfering species. Furthermore, it was found that reduction of interchain disulfide bonds occurs in the ESI source dependent on capillary voltage and solvent composition. This phenomenon was systematically evaluated and compared with the results obtained from reduction in the electrochemical cell.
Collapse
Affiliation(s)
- Simone Nicolardi
- Center for Proteomics and Metabolomics, Leiden University Medical Center , Albinusdreef 2, 2300 RC Leiden, The Netherlands
| | | | | | | |
Collapse
|
136
|
Wiegandt A, Meyer B. Unambiguous Characterization of N-Glycans of Monoclonal Antibody Cetuximab by Integration of LC-MS/MS and 1H NMR Spectroscopy. Anal Chem 2014; 86:4807-14. [DOI: 10.1021/ac404043g] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Affiliation(s)
- Alena Wiegandt
- Organic Chemistry, Department
of Chemistry, University of Hamburg, Martin-Luther-King-Platz 6, 20146 Hamburg, Germany
| | - Bernd Meyer
- Organic Chemistry, Department
of Chemistry, University of Hamburg, Martin-Luther-King-Platz 6, 20146 Hamburg, Germany
| |
Collapse
|
137
|
Fornelli L, Ayoub D, Aizikov K, Beck A, Tsybin YO. Middle-Down Analysis of Monoclonal Antibodies with Electron Transfer Dissociation Orbitrap Fourier Transform Mass Spectrometry. Anal Chem 2014; 86:3005-12. [DOI: 10.1021/ac4036857] [Citation(s) in RCA: 129] [Impact Index Per Article: 12.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- Luca Fornelli
- Biomolecular
Mass Spectrometry Laboratory, Ecole Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland
| | - Daniel Ayoub
- Biomolecular
Mass Spectrometry Laboratory, Ecole Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland
| | | | - Alain Beck
- Centre d’Immunologie Pierre Fabre, 74160 St. Julien-en-Genevois, France
| | - Yury O. Tsybin
- Biomolecular
Mass Spectrometry Laboratory, Ecole Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland
| |
Collapse
|
138
|
Reichert JM, Beck A, Lugovskoy AA, Wurch T, Coats S, Brezski RJ. 9th annual European Antibody Congress, November 11-13, 2013, Geneva, Switzerland. MAbs 2014; 6:309-26. [PMID: 24492298 PMCID: PMC7098616 DOI: 10.4161/mabs.27903] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
The annual European Antibody Congress (EAC) has traditionally been the key event for updates on critical scientific advances in the antibody field, and 2013 was no exception. Organized by Terrapinn, the well-attended meeting featured presentations on considerations for developing antibodies and antibody-like therapeutics, with separate tracks for antibody-drug conjugates, naked antibodies, and multispecific antibodies or protein scaffolds. The overall focus of the EAC was current approaches to enhance the functionality of therapeutic antibodies or other targeted proteins, with the ultimate goal being improvement of the safety and efficacy of the molecules as treatments for cancer, immune-mediated disorders and other diseases. Roundtable discussion sessions gave participants opportunities to engage in group discussions with industry leaders from companies such as Genmab, Glenmark Pharmaceuticals, MedImmune, Merrimack Pharmaceuticals, and Pierre Fabre. As the 2013 EAC was co-located with the World Biosimilar Congress, participants also received an update on European Medicines Agency guidelines and thoughts on the future direction and development of biosimilar antibodies in the European Union.
Collapse
Affiliation(s)
| | - Alain Beck
- Centre d'Immunologie Pierre Fabre; Saint Julien en Genevois, France
| | | | - Thierry Wurch
- Institut de Recherches SERVIER; Oncology R&D Unit, F-78290; Croissy-sur-Seine, France
| | | | | |
Collapse
|
139
|
Beck A, Reichert JM. Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry. MAbs 2013; 5:621-3. [PMID: 23924791 PMCID: PMC3851211 DOI: 10.4161/mabs.25864] [Citation(s) in RCA: 102] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
In a defining moment for the European Medicines Agency (EMA) and the biopharmaceutical industry, on June 27, 2013 EMA's Committee for Medicinal Products for Human Use adopted a positive opinion for two biosimilar infliximab products (Celltrion's Remsima® and Hospira's Inflectra®), and recommended that they be approved for marketing in the European Union (EU). The European Commission's decision on an application is typically issued 67 d after an opinion is provided; thus, decisions are expected in early September 2013. If approved, the products will comprise the first biosimilar antibody made available to patients in a highly regulated market, although launch may be delayed due to an extension of the reference product's (Remicade®) patent in the EU.
Collapse
Affiliation(s)
- Alain Beck
- Centre d'Immunologie Pierre Fabre; Saint-Julien-en-Genevois, France
| | | |
Collapse
|